Citigroup Inc. Has $23.45 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Citigroup Inc. raised its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 63.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 621,079 shares of the company's stock after buying an additional 241,871 shares during the quarter. Citigroup Inc. owned 0.48% of Vaxcyte worth $23,452,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PCVX. Capital Research Global Investors grew its holdings in Vaxcyte by 26.8% in the 4th quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock valued at $508,393,000 after buying an additional 1,312,302 shares in the last quarter. Paradigm Biocapital Advisors LP increased its stake in shares of Vaxcyte by 57.3% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company's stock valued at $116,469,000 after buying an additional 518,255 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Vaxcyte in the fourth quarter valued at about $39,846,000. Hood River Capital Management LLC acquired a new stake in shares of Vaxcyte in the fourth quarter valued at about $32,862,000. Finally, Ameriprise Financial Inc. increased its stake in shares of Vaxcyte by 104.7% in the fourth quarter. Ameriprise Financial Inc. now owns 716,773 shares of the company's stock valued at $58,675,000 after buying an additional 366,622 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PCVX has been the subject of several recent analyst reports. Cantor Fitzgerald initiated coverage on Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating for the company. Cowen reaffirmed a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX opened at $30.00 on Wednesday. The business's 50 day simple moving average is $34.23 and its two-hundred day simple moving average is $47.59. The firm has a market cap of $3.89 billion, a P/E ratio of -7.30 and a beta of 1.21. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period last year, the company posted ($1.10) earnings per share. On average, equities analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.